REG - Oncimmune Hldgs PLC - Grant of Options and PDMR Dealing

Oncimmune HoldingsAnnouncement

07/11/2023 16:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231107:nRSG6878Sa&default-theme=true

RNS Number : 6878S  Oncimmune Holdings PLC  07 November 2023

7 NOVEMBER 2023

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

Grant of Options and PDMR Dealing

 

 

Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company
to the pharmaceutical and biotechnology industry, today announces that as part
of its management incentivisation scheme, options ("Options") to subscribe for
589,971 ordinary shares of £0.01 each in the Company ("Ordinary Shares") were
granted on 7 November 2023 to Martin Gouldstone, Chief Executive Officer.

 

Following this grant, Mr Gouldstone holds Options over a total of 589,971
Ordinary Shares, representing approximately 0.8 per cent of the Company's
issued share capital of 74,142,147.  Other than the grant of the Options,
neither Mr Gouldstone nor any of his connected persons have any beneficial
interest in Ordinary Shares.

 

The Options have been granted under the Oncimmune Holdings Plc 2016 Unapproved
and EMI Share Option Plan, have an exercise price of £0.1695, being the
closing price of Ordinary Shares on 6 November 2023 and vest annually in
five equal parts from the date of grant until the fifth anniversary of the
grant.

 

This announcement, including the notification below, is made in accordance
with the requirements of Article 19 of the UK Market Abuse Regulation.

 

Notification and public disclosure of transactions by person discharging
managerial responsibilities and persons closely associated with them.

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Mr Martin Gouldstone

 2    Reason for the notification

 a)   Position/status                                              Chief Executive Officer

 b)   Initial notification /Amendment                              Initial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Oncimmune Holdings plc

 b)   LEI                                                          213800HCYIWT6YPI1I02

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of £0.01 each

      Identification code                                          ISIN: GB00BYQ94H38

 b)   Nature of the transaction                                    Grant of options

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     £0.1695           589,971

 d)   Aggregated information                                       N/A - single transaction

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      7 November 2023

 f)   Place of the transaction                                     Outside a trading venue

 

 

For further information:

contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)

 

Singer Capital Markets (Nominated Adviser and Broker)

Phil Davies, Harry Gooden, James Fischer

+44 (0)20 7496 3000

 

Zeus (Joint Broker)

Dominic King, Victoria Ayton, Dan Bate

+44 (0)20 3829 5000

+44 (0)20 3727 1000

 

About Oncimmune

 

Oncimmune is a global leader in immune biomarkers and immunodiagnostics,
offering autoantibody biomarker profiling in immunooncology, autoimmune and
infectious diseases. Through its ImmunoINSIGHTS™ technology platform, the
Company provides insights and analytics to discover and validate novel
biomarkers, improve treatment responses and adverse event (irAE) prediction,
patient screening and diagnostic accuracy.

Oncimmune is headquartered in the UK, with its discovery and development
facility based in Dortmund, Germany and a business development team based in
the US and Europe.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFSUFMWEDSESF